Sudden death in a traveler following halofantrine administration - Togo, 2000

JAMA

Volumn 285, Issue 14, 2001, Pages 1836-

  Irons, D ^a   Morrow, J ^b,c,d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY MEDICAL CENTER   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIMALARIAL AGENT; ATOVAQUONE PLUS PROGUANIL; DIRITHROMYCIN; FANSIDAR; HALOFANTRINE; MEFLOQUINE; PHENANTHRENE DERIVATIVE; QUININE;

CARDIOMYOPATHY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; LONG QT SYNDROME; MALARIA; MALARIA CONTROL; PRIORITY JOURNAL; SELF MEDICATION; SHORT SURVEY; SUDDEN DEATH; TRAVEL;

EID: 0035843620     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.14.1836     Document Type: Short Survey

References (10)

1. Cardiac actions of erythromycin: Influence of female sex
2. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria
3. Is halofantrine still advisable in malaria attacks?
4. Cardiac complications of halofantrine: A prospective study of 20 patients
5. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria
6. Cardiac effects of antimalarial treatment with halofantrine
7. Sudden deaths while on halofantrine treatment - A report of two cases from Peshawar
8. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy